Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
MYO 
Myomo Inc (MYO)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/30/2025: MYO (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
5 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $8.7
1 Year Target Price $8.7
| 3 | Strong Buy |
| 2 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 62.18% | Avg. Invested days 37 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 06/30/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 81.31M USD | Price to earnings Ratio - | 1Y Target Price 8.7 |
Price to earnings Ratio - | 1Y Target Price 8.7 | ||
Volume (30-day avg) 5 | Beta 1.49 | 52 Weeks Range 2.15 - 7.17 | Updated Date 06/30/2025 |
52 Weeks Range 2.15 - 7.17 | Updated Date 06/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.14 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -15.05% | Operating Margin (TTM) -35.81% |
Management Effectiveness
Return on Assets (TTM) -12.72% | Return on Equity (TTM) -35.68% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 68058714 | Price to Sales(TTM) 2.1 |
Enterprise Value 68058714 | Price to Sales(TTM) 2.1 | ||
Enterprise Value to Revenue 1.76 | Enterprise Value to EBITDA -0.82 | Shares Outstanding 35978900 | Shares Floating 28458608 |
Shares Outstanding 35978900 | Shares Floating 28458608 | ||
Percent Insiders 7.05 | Percent Institutions 60.47 |
Analyst Ratings
Rating 3 | Target Price 8.7 | Buy 2 | Strong Buy 3 |
Buy 2 | Strong Buy 3 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Myomo Inc
Company Overview
History and Background
Myomo Inc. was founded in 2004 and is a commercial-stage medical robotics company focused on restoring function for those suffering from neurological disorders such as stroke, spinal cord injury, and brachial plexus injury. The company's technology is based on research from MIT.
Core Business Areas
- MyoPro: MyoPro is a powered arm brace designed to help individuals with upper extremity paralysis or weakness regain movement and independence. It's a custom-fitted orthosis that uses sensors to detect a user's muscle signals and translate them into movement of the arm and hand.
Leadership and Structure
Paul R. Gudonis is the Chairman and CEO of Myomo. The company has a typical corporate structure with departments for sales, marketing, engineering, manufacturing, and finance.
Top Products and Market Share
Key Offerings
- MyoPro: MyoPro is Myomo's primary product, a custom-fitted myoelectric arm brace. Market share data is not publicly available, but Myomo is a significant player in the myoelectric orthosis market. Competitors include Ottobock and Fillauer.
Market Dynamics
Industry Overview
The medical robotics and rehabilitation equipment industry is growing, driven by an aging population, increasing prevalence of neurological disorders, and technological advancements. Reimbursement policies and regulatory hurdles present challenges.
Positioning
Myomo is positioned as a leading provider of myoelectric upper extremity orthoses. Its competitive advantage lies in its proprietary technology and custom-fitting process.
Total Addressable Market (TAM)
The TAM for upper extremity rehabilitation devices is estimated to be in the billions of dollars globally. Myomo is positioned to capture a portion of this market through direct sales and partnerships.
Upturn SWOT Analysis
Strengths
- Proprietary myoelectric technology
- Custom-fitting process
- Established relationships with rehabilitation centers
- FDA-cleared product
Weaknesses
- Limited financial resources
- Small sales team
- Dependence on reimbursement approvals
- History of net losses
Opportunities
- Expanding market for rehabilitation devices
- Increasing awareness of myoelectric technology
- Potential for partnerships with larger medical device companies
- Geographic expansion
- Development of new products and applications
Threats
- Competition from larger medical device companies
- Changes in reimbursement policies
- Technological obsolescence
- Economic downturn
Competitors and Market Share
Key Competitors
- OTTOY
- OSSUR.CO
Competitive Landscape
Myomo faces competition from larger, more established medical device companies. Myomo's advantage is in its specialization in myoelectric upper extremity orthoses. They need to improve cash flow and reduce losses.
Growth Trajectory and Initiatives
Historical Growth: Historical growth trends require access to up-to-date financial information.
Future Projections: Future projections require access to up-to-date analyst forecasts.
Recent Initiatives: Recent initiatives include expanding sales efforts and securing additional reimbursement approvals.
Summary
Myomo Inc. is a specialized medical robotics company with a promising technology in myoelectric upper extremity orthoses. Its strengths lie in its proprietary technology and custom-fitting process. However, the company faces challenges related to limited financial resources and dependence on reimbursement approvals. Myomo needs to carefully manage its expenses and secure additional funding to capitalize on its market opportunities.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings, industry reports, analyst reports.
Disclaimers:
The data and analysis provided are based on available information and are subject to change. This is not financial advice; consult with a financial professional before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Myomo Inc
Exchange NYSE MKT | Headquaters Burlington, MA, United States | ||
IPO Launch date 2017-06-12 | President, CEO & Chairman Mr. Paul R. Gudonis | ||
Sector Healthcare | Industry Medical Devices | Full time employees 184 | Website https://myomo.com |
Full time employees 184 | Website https://myomo.com | ||
Myomo, Inc., a wearable medical robotics company, designs, develops, and produces myoelectric orthotics for people with neuromuscular disorders in the United States, Germany, and internationally. The company offers MyoPro, a myoelectric-controlled upper limb brace or orthosis product used for supporting a patient's weak or paralyzed arm to enable and improve functional activities of daily living. It also provides MyoPro 2 that includes control technology, configuration software and user interface, and pop-out battery for extended use of the brace; and MyoPro2+, which comprises 3D printed orthotics capability, software enhancements, and a design for donning and doffing of the device. Its products are designed to help improve function in adults and adolescents with neuromuscular conditions due to brachial plexus injury, stroke, traumatic brain injury, spinal cord injury, and other neurological disorders. The company sells its products through various sales channels, including orthotics and prosthetics providers, the veteran's administration, and distributors. Myomo, Inc. was incorporated in 2004 and is headquartered in Burlington, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.